Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $6.3M fell 12.1% year over year, ahead of the -34.0% change in trailing-twelve-month accounts receivables. Sequentially, it rose 5241.5% from the prior quarter.
Context
- Accounts receivables amounted to 3.4% of revenue in FY2025, down 6.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -12.1% holds above the trailing-twelve-month pace of -34.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.74M USD
- Year-over-year change
- +128.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.74M | +128.0% |
| FY2024 | 2024-12-31 | (6.21M) | -27.9% |
| FY2023 | 2023-12-31 | (4.85M) | -2454.7% |
| FY2022 | 2022-12-31 | (190K) | +97.9% |
| FY2021 | 2021-12-31 | (8.88M) | — |
Accounts Receivables vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.0% is the 3rd highest of 7, against a peer median of -96.7%.
- Accounts receivables amounts to 1.7% of revenue for OCUL, versus a peer median of 12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $89.24M USD | +37.3% | +15.9% | 1.7% | |
| LTM Jun 2026 | $60.95M USD | +79.6% | +156.6% | 9.9% | |
| LTM Apr 2026 | $42.26M USD | -270.2% | — | 14.6% | |
| LTM Mar 2026 | $24.36M USD | -50.7% | — | 9.1% | |
| LTM Mar 2026 | $19.05M USD | -355.9% | +58.8% | 250.2% | |
| LTM Mar 2026 | $968.41K USD | — | — | 290.7% | |
| LTM Mar 2026 | $874K USD | -34.0% | — | 1.7% | |
| LTM Mar 2026 | CHF 272.05K CHF | -142.6% | — | 54.0% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $8K USD | — | — | — |
| LTM Sep 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OCUL) | — | -96.7% | +58.8% | 12.2% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.